FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma

FDA approved olaparib (LYNPARZA ®, AstraZeneca) for maintenance treatment of patients with gBRCAm metastatic pancreatic adenocarcinoma, as detected by an FDA-approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

Source: FDA Center for Drug Evaluation and Research - What's New - December 30, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news